System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Irfan Cicin is an expert in Oncology at Haseki Eğitim ve Araştırma Hastanesi (Turkey). As of July 2026, ScienceLeadR ranks Irfan Cicin in the top 1% of experts worldwide for Bronchial Neoplasms, Carcinoma and Lung Neoplasms. Irfan Cicin has authored 332 publications, the most recent in 2026, and is an investigator in 42 clinical trials, 2 of them ongoing. SLR score: 1,631 (community average: 125). How the SLR is computed.

LeadR Profile

Irfan Cicin Haseki Eğitim ve Araştırma Hastanesi Turkey
1 631 ScienceLeadR Reputation 1631

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pulmonology - Pharmacy - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1997 - 2026
Source: PubMed

Istinye University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 332

Citations

Citations: 28 791 1st author: 24 Last author: 83 Unique author: 1

Main journals

J Clin Oncol 44
Ann Oncol 32
J Thorac Oncol 24
N Engl J Med 19
J BUON 11

Best Journals

J Clin Oncol 30
Ann Oncol 19
N Engl J Med 16

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1.
PMID 42529322 — confidence intervals, lung, safety, carcinoma, non-small-cell lung, drug therapy, drug-related side effects and adverse reactions, histology, therapeutics, chemotherapy		JTO Clin Res Rep20260
Preimplantation genetic testing (PGT-M) awareness in BRCA-positive individuals in Türkiye: a dual physician-patient survey.
PMID 42414499 — research design, genetic testing, physicians, counseling		Sci Rep20261
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.
PMID 42368479 — safety, neoplasms, carcinoma, non-small-cell lung, therapeutics		JTO Clin Res Rep20262
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study.
PMID 42309024 — breast neoplasms, neoplasms, drug therapy, breast, therapeutics, tamoxifen, chemotherapy		Breast20260
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial.
PMID 42240984 — cells, lung, safety, neoplasms, drug therapy, lung neoplasms, small cell lung carcinoma, therapeutics, chemotherapy		JAMA Oncol20260

Clinical Studies 42

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 38
N/A 2
Phase 2 2

By status:

Completed 25
Active not recruiting 16
Terminated 1

By type:

Interventional 40
Observational 2

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 1
multicentricup10 36

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
NCT05089734 — cells, lung, docetaxel, neoplasms, carcinoma, non-small-cell lung, drug therapy, immunotherapy, lung neoplasms, small cell lung carcinoma, chemotherapy, carcinoma		Phase 3Active not recruiting2021
A Study of Imlunestrant Investigator s Choice of Endocrine Therapy and Imlunestrant Plus Abemaciclib in Participants With ER HER2 Advanced Breast Cancer
NCT04975308 — fulvestrant, estrogens, breast neoplasms, receptors, estrogen, neoplasms, neoplasm metastasis, breast, work, therapeutics		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS